Axsome Therapeutics (AXSM) Debt to Equity: 2022-2025
Historic Debt to Equity for Axsome Therapeutics (AXSM) over the last 4 years, with Sep 2025 value amounting to $2.55.
- Axsome Therapeutics' Debt to Equity rose 25.67% to $2.55 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.55, marking a year-over-year increase of 25.67%. This contributed to the annual value of $3.31 for FY2024, which is 243.16% up from last year.
- Axsome Therapeutics' Debt to Equity amounted to $2.55 in Q3 2025, which was down 0.83% from $2.57 recorded in Q2 2025.
- Axsome Therapeutics' 5-year Debt to Equity high stood at $6.54 for Q2 2022, and its period low was $0.64 during Q3 2022.
- For the 3-year period, Axsome Therapeutics' Debt to Equity averaged around $1.89, with its median value being $1.81 (2024).
- Per our database at Business Quant, Axsome Therapeutics' Debt to Equity slumped by 89.96% in 2023 and then soared by 243.16% in 2024.
- Axsome Therapeutics' Debt to Equity (Quarterly) stood at $0.91 in 2022, then climbed by 5.66% to $0.97 in 2023, then soared by 243.16% to $3.31 in 2024, then grew by 25.67% to $2.55 in 2025.
- Its Debt to Equity stands at $2.55 for Q3 2025, versus $2.57 for Q2 2025 and $3.57 for Q1 2025.